Budget 2018-19

  Eight elderly workers at a German care home were mistakenly injected with five times the recommended dose of the Pfizer/Biontech vaccine, local authorities said Eight elderly workers at a German care home were mistakenly injected with five times the recommended dose of the Pfizer/Biontech vaccine, local authorities said Monday. The incident happened on Sunday in the northeastern city of Stralsund in the Vorpommern-Ruegen district. District chief Stefan Kerth said in a statement that he regretted the mishap. “I deeply regret the incident. This single event is the result of an individual mistake. I hope that all those affected will not develop serious side-effects,” he said. Those injected with the drug were aged between 66 and 82. They were sent home as soon as the mistake came to light. Four developed flu-like symptoms and were hospitalized for observation. The district authority pointed out that the vaccine’s German developer, Biontech, had used higher doses during the first pha...

  India has dealt with the ‘worst crisis’ in decades along its border with China with ‘firmness and maturity’ India has dealt with the “worst crisis” in decades along its border with China with “firmness and maturity” despite facing the challenge of the coronavirus pandemic, Foreign Secretary Harsh Vardhan Shringla said on Thursday. In an address at a leading think-tank in Paris, Shringla mentioned two recent terrorist incidents in France, one of which he said had its origins in Pakistan, noting that the civilised world needs to act with firmness to address the threat of terrorism. Shringla said India and France face similar non-traditional security threats in the form of radicalism and terrorism, and the fight today is not against specific communities or individuals but against a “radical politico-religious ideology”. Delving into major geo-strategic issues, he said the immediate challenges have not been able to distract India from broader strategic goals, especially in the Indo-P...

  Takeda Pharmaceutical said an alliance of drugmakers it spearheads has enrolled its first patient in a global clinical trial of a blood plasma treatment for Covid-19 after months of regulatory delays TOKYO (Reuters) – Japan’s Takeda Pharmaceutical Co said on Friday an alliance of drugmakers it spearheads has enrolled its first patient in a global clinical trial of a blood plasma treatment for COVID-19 after months of regulatory delays. The phase 3 trial by the group, known as the CoVIg Plasma Alliance, aims to enroll 500 adult patients from the United States, Mexico and 16 other countries, according to a statement. Patients will be treated with Gilead Science Inc’s Remdesivir alongside the  plasma treatment , which will be provided by CSL Behring, Takeda and two other companies. “We are hopeful that data from the clinical trial will be available before the end of the year,” Bill Mezzanotte, chief medical officer of CSL Behring, said in the release. The group had aimed to beg...